---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-014334"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:21:02.897886+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# uniQure Q3 net loss $44.4M; cash runway through 2027; FDA meeting for Huntington gene therapy

## Summary
- Net loss $44.4M ($0.91/share) vs $89.6M ($1.88) in Q3 2023; revenue $2.3M (up from $1.4M).
- Cash $435.2M as of Sep 30; retired $50M debt; expects cash runway through end of 2027.
- Sold Lexington facility and restructured, cutting ~65% of roles (300) and reducing cash burn by $70M/year.
- Type B FDA meeting scheduled late Nov 2024 to discuss accelerated pathway for AMT-130 in Huntington's disease.
- Positive interim data at 24 months: AMT-130 high dose showed significant slowing of disease progression (p=0.007) and NfL reduction (p=0.02).

## SEC filing metadata
- accession: 0001558370-24-014334
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000155837024014334/0001558370-24-014334-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000155837024014334/qure-20241105x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-014334
- JSON: https://secwatch.observer/filing/0001558370-24-014334.json
- Plain text: https://secwatch.observer/filing/0001558370-24-014334.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.